<DOC>
	<DOCNO>NCT02049060</DOCNO>
	<brief_summary>This prospective , open-label , mono-centric , phase I-Ib trial Tivantinib combination Pemetrexed Carboplatin first-line therapy patient advance metastatic cancer suitable Carboplatin Pemetrexed regimen part specific therapy .</brief_summary>
	<brief_title>Study Combination Tivantinib Plus Pemetrexed Carboplatin</brief_title>
	<detailed_description>This prospective , open-label , mono-centric , phase I-Ib trial Tivantinib combination Pemetrexed Carboplatin first-line therapy patient advance metastatic cancer suitable Carboplatin Pemetrexed regimen part specific therapy.This trial conduct determine maximum tolerate dose ( MTD ) , safety/tolerability , pharmacokinetics preliminary anti-tumor activity escalate dos Tivantinib combination standard fix dose Carboplatin Pemetrexed . The dose-escalation stage follow expansion stage MTD good define toxicity clinical activity . MTD define high dose level &lt; 33 % 6 patient experience DLT . Eligible patient enrol treated accord follow 3 + 3 design start cohort 0 : - 1 level : Tivantinib 120 mg p.o . BID + Carboplatin AUC 5 i.v . day 1 every 3 week + Pemetrexed 500 mg/mq i.v . day 1 every 3 week 0 level : Tivantinib 240 mg p.o . BID + Carboplatin AUC 5 i.v . day 1 every 3 week + Pemetrexed 500 mg/mq i.v . day 1 every 3 week - 1 level : Tivantinib 360 mg p.o . BID + Carboplatin AUC 5 i.v . day 1 every 3 week + Pemetrexed 500 mg/mq i.v . day 1 every 3 week If frequency DLTs encounter dose-level +1 fulfil MTD definition , Tivantinib 360 mg bid combination Carboplatin AUC 5 Pemetrexed 500 mg/mq accept recommend dose phase IItrials . Treatment continue basis tumor assessment . Patients stable disease , complete partial response continue treatment progressive disease , unacceptable toxicity , patient physician decision . For chemotherapy agent , however , maximum 6 cycle administer . Tivantinib continue progressive disease , unacceptable toxicity , patient physician decision . Toxicity grade accord National Cancer Institute Common Toxicity Criteria ( NCI-CTC ) version 3 . Following dose-escalation phase study , additional patient ( order reach total 13 patient MPM 18 patient NSCLC treat MTD/recommended dose phase Ib trial ) accrue expansion stage trial , assess preliminary anti-tumor activity Tivantinib combination Carboplatin ( AUC 5 ) Pemetrexed ( 500 mg/mq ) primarily .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients must diagnose MPM non squamous NSCLC . 2 . Inoperable disease accord local surgeon , previously treat chemotherapy ; patient relapsed/progressed previous surgery also evaluable inclusion . 3 . Age &gt; 18 . 4 . ECOG Performance Status 01 life expectancy least 12 week . 5 . Measurable and/or evaluable lesion accord modified RECIST criterion [ 51 ] . 6 . Written informed consent . 7 . Patients must accessible treatment follow . Patients register trial must treat follow participate center . 8 . Patients must use effective contraception study last least one month end treatment sex . 9 . Laboratory requirement : Neutrophils &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L Total bilirubin &lt; 1.5 time uppernormal limit ( UNL ) Institutional normal value , AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 x UNL , &lt; 5 x UNL case liver metastasis , alkaline phosphatase &lt; 2.5 x UNL , &lt; 5 x UNL case liver metastasis , &lt; 10 x UNL case bone metastasis . Creatinine clearance &gt; 50 mL/min 1 . Any prior chemotherapy ( include intracavitary administration ) . 2 . Symptomatic and/or unstable preexist brain metastases.To enrol study , subject must confirmation stable disease MRI computer tomography ( CT ) scan within 4 week day 1 cycle 1 treatment CNS metastases well controlled steroid , anti epileptic symptomrelieving medication 3 . Serious nonhealing wound ulcer . 4 . Evidence bleed diathesis coagulopathy . 5 . Uncontrolled hypertension . 6 . Clinically significant ( i.e . active ) cardiovascular disease , example cerebrovascular accident ( &lt; 6 month ) , myocardial infarction ( &lt; 6 month ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication . 7 . Current treatment anticoagulant therapeutic purpose . 8 . Treatment investigational drug within 30 day prior enrolment . 9 . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ 10 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study . 11 . Pregnant lactating woman . Women childbearing potential either positive pregnancy test baseline . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Sexually active male female ( childbearing potential ) unwilling practice contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MPM</keyword>
	<keyword>NSCLC</keyword>
</DOC>